The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to Tf R, the transferrin receptor, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as lymphoma or leukaemia.